Medicinal chemistry approaches to personalized medicine / (Record no. 207126)
[ view plain ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 05271cam a2200709Ia 4500 |
| 001 - CONTROL NUMBER | |
| control field | ocn864744144 |
| 003 - CONTROL NUMBER IDENTIFIER | |
| control field | OCoLC |
| 005 - DATE AND TIME OF LATEST TRANSACTION | |
| control field | 20171105083452.0 |
| 006 - FIXED-LENGTH DATA ELEMENTS--ADDITIONAL MATERIAL CHARACTERISTICS | |
| fixed length control field | m o d |
| 007 - PHYSICAL DESCRIPTION FIXED FIELD--GENERAL INFORMATION | |
| fixed length control field | cr cnu---unuuu |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION | |
| fixed length control field | 131206s2014 gw ob 001 0 eng d |
| 020 ## - INTERNATIONAL STANDARD BOOK NUMBER | |
| International Standard Book Number | 9783527677283 |
| Qualifying information | (electronic bk.) |
| 020 ## - INTERNATIONAL STANDARD BOOK NUMBER | |
| International Standard Book Number | 3527677283 |
| Qualifying information | (electronic bk.) |
| 020 ## - INTERNATIONAL STANDARD BOOK NUMBER | |
| International Standard Book Number | 9783527677252 |
| Qualifying information | (electronic bk.) |
| 020 ## - INTERNATIONAL STANDARD BOOK NUMBER | |
| International Standard Book Number | 3527677259 |
| Qualifying information | (electronic bk.) |
| 020 ## - INTERNATIONAL STANDARD BOOK NUMBER | |
| International Standard Book Number | 1306168902 |
| Qualifying information | (electronic bk.) |
| 020 ## - INTERNATIONAL STANDARD BOOK NUMBER | |
| International Standard Book Number | 9781306168908 |
| Qualifying information | (electronic bk.) |
| 020 ## - INTERNATIONAL STANDARD BOOK NUMBER | |
| International Standard Book Number | 9783527333943 |
| 020 ## - INTERNATIONAL STANDARD BOOK NUMBER | |
| International Standard Book Number | 3527333940 |
| 020 ## - INTERNATIONAL STANDARD BOOK NUMBER | |
| International Standard Book Number | 9783527677269 |
| Qualifying information | (Mobi) |
| 020 ## - INTERNATIONAL STANDARD BOOK NUMBER | |
| International Standard Book Number | 3527677267 |
| Qualifying information | (Mobi) |
| 020 ## - INTERNATIONAL STANDARD BOOK NUMBER | |
| International Standard Book Number | 9783527677276 |
| Qualifying information | (ePub) |
| 020 ## - INTERNATIONAL STANDARD BOOK NUMBER | |
| International Standard Book Number | 3527677275 |
| Qualifying information | (ePub) |
| 029 1# - OTHER SYSTEM CONTROL NUMBER (OCLC) | |
| OCLC library identifier | DEBBG |
| System control number | BV043396386 |
| 029 1# - OTHER SYSTEM CONTROL NUMBER (OCLC) | |
| OCLC library identifier | DEBSZ |
| System control number | 43157054X |
| 029 1# - OTHER SYSTEM CONTROL NUMBER (OCLC) | |
| OCLC library identifier | NZ1 |
| System control number | 15495746 |
| 029 1# - OTHER SYSTEM CONTROL NUMBER (OCLC) | |
| OCLC library identifier | NZ1 |
| System control number | 15905579 |
| 035 ## - SYSTEM CONTROL NUMBER | |
| System control number | (OCoLC)864744144 |
| Canceled/invalid control number | (OCoLC)870511683 |
| -- | (OCoLC)961643563 |
| -- | (OCoLC)962637366 |
| 037 ## - SOURCE OF ACQUISITION | |
| Stock number | 548141 |
| Source of stock number/acquisition | MIL |
| 040 ## - CATALOGING SOURCE | |
| Original cataloging agency | IDEBK |
| Language of cataloging | eng |
| Description conventions | pn |
| Transcribing agency | IDEBK |
| Modifying agency | EBLCP |
| -- | DG1 |
| -- | N$T |
| -- | YDXCP |
| -- | OCLCF |
| -- | OCLCQ |
| -- | DEBSZ |
| -- | COO |
| -- | DEBBG |
| -- | OCLCQ |
| -- | CDX |
| 049 ## - LOCAL HOLDINGS (OCLC) | |
| Holding library | MAIN |
| 050 #4 - LIBRARY OF CONGRESS CALL NUMBER | |
| Classification number | RS403 |
| 050 #4 - LIBRARY OF CONGRESS CALL NUMBER | |
| Classification number | RM111 |
| Item number | .L384 2013 |
| 060 #4 - NATIONAL LIBRARY OF MEDICINE CALL NUMBER | |
| Classification number | QV 744 |
| 072 #7 - SUBJECT CATEGORY CODE | |
| Subject category code | MED |
| Subject category code subdivision | 071000 |
| Source | bisacsh |
| 082 04 - DEWEY DECIMAL CLASSIFICATION NUMBER | |
| Classification number | 615.1/9 |
| Edition number | 23 |
| 245 00 - TITLE STATEMENT | |
| Title | Medicinal chemistry approaches to personalized medicine / |
| Statement of responsibility, etc. | edited by Karen Lackey and Bruce D. Roth. |
| Medium | [electronic resource] |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. (IMPRINT) | |
| Place of publication, distribution, etc. | Weinheim : |
| Name of publisher, distributor, etc. | Wiley-VCH, |
| Date of publication, distribution, etc. | 2014. |
| 300 ## - PHYSICAL DESCRIPTION | |
| Extent | 1 online resource. |
| 336 ## - CONTENT TYPE | |
| Content type term | text |
| Content type code | txt |
| Source | rdacontent |
| 337 ## - MEDIA TYPE | |
| Media type term | computer |
| Media type code | c |
| Source | rdamedia |
| 338 ## - CARRIER TYPE | |
| Carrier type term | online resource |
| Carrier type code | cr |
| Source | rdacarrier |
| 490 1# - SERIES STATEMENT | |
| Series statement | Medicinal chemistry ; |
| Volume/sequential designation | Volume 59 |
| 504 ## - BIBLIOGRAPHY, ETC. NOTE | |
| Bibliography, etc | Includes bibliographical references and index. |
| 505 0# - FORMATTED CONTENTS NOTE | |
| Formatted contents note | Methods and Principles in Medicinal Chemistry; Title Page; Copyright; List of Contributors; Foreword; Preface; A Personal Foreword; Acronyms; Chapter 1: Medicinal Chemistry Approaches to Creating Targeted Medicines; 1.1 Introduction; 1.2 Role of Medicinal Chemistry in Drug Discovery; 1.3 Evolution of Molecular Design for Subsets of Patients; 1.4 Combinations for Effective Therapies; 1.5 Biomarkers in Targeting Patients; 1.6 Emerging Field of Epigenetics; 1.7 Systems Chemical Biology; 1.8 Theranostics and Designing Drug Delivery Systems |
| 505 8# - FORMATTED CONTENTS NOTE | |
| Formatted contents note | 1.9 Rapid Progress in Further Personalizing Medicine ExpectedReferences; Chapter 2: Discovery of Predictive Biomarkers for Anticancer Drugs; 2.1 Introduction; 2.2 "Oncogene Addiction" as a Paradigm for Clinical Implementation of Predictive Biomarkers; 2.3 Cancer Cell Lines as a Model System for Discovery of Predictive Biomarkers; 2.4 Modeling Drug Resistance to Discover Predictive Biomarkers; 2.5 Discovery of Predictive Biomarkers in the Context of Treatment Combinations; 2.6 Discovery of Predictive Biomarkers for Antiangiogenic Agents; 2.7 Gene Expression Signatures as Predictive Biomarkers |
| 505 8# - FORMATTED CONTENTS NOTE | |
| Formatted contents note | 2.8 Current Challenges in Discovering Predictive Biomarkers2.9 Future Perspective; References; Chapter 3: Crizotinib; 3.1 Introduction; 3.2 Discovery of Crizotinib ( PF -02341066) [40]; 3.3 Kinase Selectivity of Crizotinib; 3.4 Pharmacology of Crizotinib [45,46]; 3.5 Human Clinical Efficacies of Crizotinib; 3.6 Summary; References; Chapter 4: Discovery and Development of Vemurafenib: First-in-Class Inhibitor of Mutant BRAF for the Treatment of Cancer; 4.1 Background; 4.2 Discovery and Development of Vemurafenib (PLX4032); 4.3 Pharmacology; 4.4 Clinical Efficacy and Safety |
| 505 8# - FORMATTED CONTENTS NOTE | |
| Formatted contents note | 4.5 Companion Diagnostic (cobas 4800) Development4.6 Synthesis; 4.7 Summary; References; Chapter 5: Targeting Basal-Cell Carcinoma: Discovery and Development of Vismodegib ( GDC -0449), a First-in-Class Inhibitor of the Hedgehog Pathway; 5.1 Introduction; 5.2 Hedgehog and Basal-Cell Carcinoma; 5.3 Cyclopamine as an SMO Antagonist; 5.4 Small-Molecule Inhibitors of SMO; 5.5 Preclinical Characterization of Vismodegib; 5.6 Vismodegib Clinical Experience in Phase I; References; Chapter 6: G-Quadruplexes as Therapeutic Targets in Cancer; 6.1 Introduction; 6.2 Quadruplex Fundamentals |
| 505 8# - FORMATTED CONTENTS NOTE | |
| Formatted contents note | 6.3 Genomic Quadruplexes6.4 Quadruplexes in Human Telomeres; 6.5 Quadruplexes as Anticancer Targets -- Evidence from In Vivo Studies; 6.6 Native Quadruplex Structures; 6.7 Quadruplex-Small-Molecule Structures; 6.8 Developing Superior Quadruplex-Binding Ligands; 6.9 Conclusions; References; Chapter 7: Identifying Actionable Targets in Cancer Patients; 7.1 Introduction and Background; 7.2 Overview of Genomic Sequencing and Its Impact on the Identification of Actionable Mutations; 7.3 Actionable Targets by Clinical Molecular Profiling: the OICR / PMH Experience |
| 588 0# - SOURCE OF DESCRIPTION NOTE | |
| Source of description note | Print version record. |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name as entry element | Pharmaceutical chemistry. |
| 650 #7 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name as entry element | MEDICAL |
| General subdivision | Pharmacology. |
| Source of heading or term | bisacsh |
| 650 #7 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name as entry element | Pharmaceutical chemistry. |
| Source of heading or term | fast |
| Authority record control number | (OCoLC)fst01060115 |
| 655 #4 - INDEX TERM--GENRE/FORM | |
| Genre/form data or focus term | Electronic books. |
| 655 #0 - INDEX TERM--GENRE/FORM | |
| Genre/form data or focus term | Electronic books. |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Lackey, Karen. |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Roth, Bruce D. |
| 776 08 - ADDITIONAL PHYSICAL FORM ENTRY | |
| Relationship information | Print version: |
| Title | Medicinal chemistry approaches to personalized medicine. |
| Place, publisher, and date of publication | Weinheim : Wiley-VCH, 2014 |
| International Standard Book Number | 9783527677252 |
| 830 #0 - SERIES ADDED ENTRY--UNIFORM TITLE | |
| Uniform title | Medicinal chemistry ; |
| Volume number/sequential designation | Volume 59. |
| 856 40 - ELECTRONIC LOCATION AND ACCESS | |
| Uniform Resource Identifier | http://onlinelibrary.wiley.com/book/10.1002/9783527677252 |
| Public note | Wiley Online Library |
| 942 ## - ADDED ENTRY ELEMENTS (KOHA) | |
| Source of classification or shelving scheme | |
| Koha item type | Books |
No items available.